Clinical Trial Update: Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing metformin to tolvaptan for autosomal dominant polycystic kidney disease is in progress, with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• metformin (metformin)
• tolvaptan (tolvaptan)

Snippet

Sponsor: Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari | Conditions: ADPKD | Phase 3 | Status: UNKNOWN